In developing annual 20 the goal of the editors was to offer a timely critical review of the literature that has appeared in 2001 focusing mainly on novel therapeutic approaches in the areas of drugs and biologics.
Indice testuale
Section 1: Drugs. Thymidylate Synthase Inhibitors (S. Ackland); New Nucleoside Analogues in Clinical Development (W. Plunkett); Anthracyclines (L. Gianni); Tubulin Targeting Agents (W.N. Hait); Topoismerase I Interactive Agents (C.F. Stewart); Topoisomerase II Inhibitors (K. Hande); Farnesyltransferase Inhibitors (A.A. Adjei); Cyclin-Dependent Kinases as Targets for Cancer Therapy (A.M. Senderowicz); DNA-Binding Agents (Y. Nieto); The Evolving Role of Endocrine Therapy for the Treatment and Prevention of Breast Cancer (W. Gradishar); New Targets for Cancer Chemotherapy (A.J. Murgo) Section 2: Biological Response Modifiers. The Graft-versus-Tumor Effect and the Escape of Maliganancy from Immune Regulation (A.J. Barrett); Donor Lymphocyte Infusions for Hematopoitic Malignancy (S. Slavin); Diptheria Toxin Conjugate Therapy of Cancer (A.E. Frankel); Genetically Engineered T Cells as Adoptive Immunotherapy of Cancer (R.P. Junghans); Integrating IL-12 into Therapeutic Cancer Vaccines (T. Grajewski); Immunotherapy for Breast Cancer (K.L. Knutson); Immunotherapy of Melanoma (P.B. Chapman); CEA Loaded Dendritic Cell Vaccines (M.A. Morse). Section 3: Tumours. Leukemias and Plasma Cell Myeloma (P. Wiernik); Lymphomas (A. Santoro); Head and Neck Cancer (M. Al-Sarraf); Upper Gastrointestinal Tumors (K. Aiba). Cancers of the Large Bowel and Hepatobiliary Tract (T.S. d'Entremont); Malignant Neuroendocrine Tumors (E. Tiensuu); Genitourinary Malignancies (M.D. Michaelson); Breast Cancer (G. Bonadonna); Melanoma (A. Schneeberger); Sarcomas (J. Verweij); Brain Tumors (L. Ashby); Biology and Therapy of Malignant Solid Tumors in Childhood (H. van den Berg); Supportive Care (M. Markman); Aids-Associated Malignancies (M.H. Shah). Section 4: Lung Cancer. CT Screening for Lung Cancer (C. Henschke); Biology of Lung Cancer (A. Guzdar); Combined Modality of Treatment of Lung Cancer (NSCLC and SCLC) (T. Le Chevalier); Update on the Systemic Treatment of Lung Cancer (G. Giaccone); Novel Therapeutics for Advanced Non-small Cell Lung Cancer (R. Herbst); Novel therapies for the Treatment of Non-small Cell Lung Cancer (D. Johnson).
